Hatthakarnkul, P. et al. (2024) Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 10(3), e12374 VSports. (doi: 10. 1002/2056-4538. 12374) (PMID:38650367) (PMCID:PMC11035902) .
|
Text
"VSports在线直播" 306839.pdf - Published Version Available under License Creative Commons Attribution. 22MB |
Abstract
Colorectal cancer (CRC) is a heterogenous malignancy and research is focused on identifying novel ways to subtype patients. In this study, a novel classification system, tumour microenvironment score (TMS), was devised based on Klintrup–Mäkinen grade (KMG), tumour stroma percentage (TSP), and tumour budding. TMS was performed using a haematoxylin and eosin (H&E)-stained section from retrospective CRC discovery and validation cohorts (n = 1,030, n = 787). TMS0 patients had high KMG, TMS1 were low for KMG, TSP, and budding, TMS2 were high for budding, or TSP and TMS3 were high for TSP and budding. Scores were assessed for association with survival and clinicopathological characteristics VSports app下载. Mutational landscaping and Templated Oligo-Sequencing (TempO-Seq) profiling were performed to establish differences in the underlying biology of TMS. TMS was independently prognostic in both cohorts (p < 0. 001, p < 0. 001), with TMS3 predictive of the shortest survival times. TMS3 was associated with adverse clinical features including sidedness, local and distant recurrence, higher T stage, higher N stage, and presence of margin involvement. Gene set enrichment analysis of TempO-Seq data showed higher expression of genes associated with hallmarks of cancer pathways including epithelial to mesenchymal transition (p < 0. 001), IL2 STAT5 signalling (p = 0. 007), and angiogenesis (p = 0. 017) in TMS3. Additionally, enrichment of immunosuppressive immune signatures was associated with TMS3 classification. In conclusion, TMS represents a novel and clinically relevant method for subtyping CRC patients from a single H&E-stained tumour section.
| Item Type: | Articles |
|---|---|
| Additional Information: | The authors thank CRUK funding which enabled this research (Scottish Cancer Centre CTRQQR-2021/100006) and Chief Scientific Office (CSO) Scotland funding (EPD/22/13) (KP and JE). The authors would also like to acknowledge funding from Beatson Cancer Charity (22-23-055). |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Park, Mr James and Roseweir, Dr Antonia and Alexander, Mr Peter and Pennel, Dr Kathryn and Roxburgh, Professor Campbell and Hay, Miss Jennifer and Edwards, Professor Joanne and McMillan, Professor Donald and Inthagard, Jitwadee and Hatthakarnkul, Miss Phimmada and Van Wyk, Dr Hester |
| Authors: | Hatthakarnkul, P., Pennel, K., Alexander, P., Van Wyk, H., Roseweir, A., Inthagard, J., Hay, J., Andersen, D., Maka, N., Park, J., Roxburgh, C., Thuwajit, C., McMillan, D., and Edwards, J. |
| College/School: | College of Medical Veterinary and Life Sciences College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | Journal of Pathology: Clinical Research |
| Publisher: | Wiley |
| ISSN: | 2056-4538 |
| ISSN (Online): | 2056-4538 |
| Published Online: | 22 April 2024 |
| Copyright Holders: | Copyright © 2024 The Authors |
| First Published: | First published in Journal of Pathology: Clinical Research 10(3):e12374 |
| Publisher Policy: | Reproduced under a Creative Commons license |
University Staff: Request a correction | Enlighten Editors: Update this record

Funder and Project Information
Funder and Project Information